Literature DB >> 14978770

Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage.

Guenter Cichon1, Thomas Willnow, Susanne Herwig, Wolfgang Uckert, Peter Löser, Hartmut H Schmidt, Tahar Benhidjeb, Peter M Schlag, Frank Schnieders, Dagmara Niedzielska, Joerg Heeren.   

Abstract

BACKGROUND: Gene therapy of familial hypercholesterolemia (FH) requires successful transfer and lifelong expression of a functional low density lipoprotein receptor (LDLr) gene in the liver. Most of the vector systems currently employed for gene therapy use promoter elements which do not modulate transgene expression in a physiological manner.
METHODS: To study the in vivo effects of constitutive LDLr gene expression in the absence of interfering immunological reactions we established a new mouse model which combines homozygous LDLr deficiency and severe combined immune deficiency (SCID).
RESULTS: Adenovirus-mediated transfer and expression of the LDLr gene under the control of a commonly used virus-derived promoter (minimal CMV promoter) leads to prolonged reduction of serum cholesterol levels in LDLr-deficient SCID mice. During the first 10 days after gene therapy serum cholesterol drops to about 10% of pretherapeutic values. Serum cholesterol persists on this level for 2 weeks and then slowly starts to rise again. Four months after vector application serum levels have reached about 40% of pretherapeutic values. However, as early as 5 days after gene transfer, the histological analysis of liver sections revealed the formation of crystalline lipid/cholesterol deposits in the cytosol of hepatocytes. During the following 8 weeks the amount of crystals increased in size and density. The intracellular storage of lipid and cholesterol reduced cell viability and induced an accelerated loss of therapeutic DNA from mice livers as was shown in a comparative expression study employing a transgene with a different metabolic function (human alpha 1-antitrypsin).
CONCLUSIONS: The non-physiological constitutive overexpression of an LDL receptor gene induces an imbalance between the speed of LDL uptake and metabolism which leads to pathological accumulation of lipids and cholesterol in hepatocytes. To protect cells from negative effects of LDLr overexpression, future vector design should consider the use of physiologically controlled expression elements. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14978770     DOI: 10.1002/jgm.473

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  11 in total

1.  Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis.

Authors:  Sadik H Kassim; Hui Li; Luk H Vandenberghe; Christian Hinderer; Peter Bell; Dawn Marchadier; Aisha Wilson; Debra Cromley; Valeska Redon; Hongwei Yu; James M Wilson; Daniel J Rader
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

2.  Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs.

Authors:  Olivia C Hibbitt; Eileen McNeil; Michele Mp Lufino; Len Seymour; Keith Channon; Richard Wade-Martins
Journal:  Mol Ther       Date:  2009-10-27       Impact factor: 11.454

3.  LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives.

Authors:  Faisal A Al-Allaf; Charles Coutelle; Simon N Waddington; Anna L David; Richard Harbottle; Michael Themis
Journal:  Int Arch Med       Date:  2010-12-13

Review 4.  Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy.

Authors:  S P Simna; Zongchao Han
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.676

5.  An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency.

Authors:  Michele M P Lufino; Roberto Manservigi; Richard Wade-Martins
Journal:  Nucleic Acids Res       Date:  2007-08-02       Impact factor: 16.971

6.  The infectious BAC genomic DNA expression library: a high capacity vector system for functional genomics.

Authors:  Michele M P Lufino; Pauline A H Edser; Michael A Quail; Stephen Rice; David J Adams; Richard Wade-Martins
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

7.  Restoration of Physiologically Responsive Low-Density Lipoprotein Receptor-Mediated Endocytosis in Genetically Deficient Induced Pluripotent Stem Cells.

Authors:  Venkat M Ramakrishnan; Jeong-Yeh Yang; Kevin T Tien; Thomas R McKinley; Braden R Bocard; John G Maijub; Patrick O Burchell; Stuart K Williams; Marvin E Morris; James B Hoying; Richard Wade-Martins; Franklin D West; Nolan L Boyd
Journal:  Sci Rep       Date:  2015-08-26       Impact factor: 4.379

8.  Endogenous ceramide contributes to the transcytosis of oxLDL across endothelial cells and promotes its subendothelial retention in vascular wall.

Authors:  Wenjing Li; Xiaoyan Yang; Shasha Xing; Fang Bian; Wanjing Yao; Xiangli Bai; Tao Zheng; Guangjie Wu; Si Jin
Journal:  Oxid Med Cell Longev       Date:  2014-04-10       Impact factor: 6.543

9.  QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion.

Authors:  Li Peng; Chong-Shan Lv; Yun Zhao; Shao-Dong Chen; Yang Huang; Da-Wei Lu; Shu-Qiong Huang; Zong-Bao Yang; Lin-Chao Qian; Lei Wen
Journal:  Oncotarget       Date:  2017-07-07

10.  Episomal Nonviral Gene Therapy Vectors Slow Progression of Atherosclerosis in a Model of Familial Hypercholesterolemia.

Authors:  Alastair G Kerr; Lawrence Cs Tam; Ashley B Hale; Milena Cioroch; Gillian Douglas; Keith M Channon; Richard Wade-Martins
Journal:  Mol Ther Nucleic Acids       Date:  2016-11-08       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.